


Quick Update:

- Membership: 460 members
- 8th COGNO ASM a success
- Save the date for the 13th ASNO/9th COGNO ASM



COGNO

COOPERATIVE TRIALS GROUP
FOR NEURO-ONCOLOGY

Member Newsletter

Issue 20

Summer 2015

Inside this issue:

Chairman's Message	1
COGNO 8 th ASM Report	1, 6-8
Getting to Know COGNO's MC Members: A/Prof Matthew Foote	2
Study & Trial Updates	3
New Concepts/ Trials in Development	4
Membership Update	4
BCBA Update	4
QoL Office Update	4
QoL Checklist Workshop Report	5
Race4Stace	5
13 th ASNO/ 9 th COGNO ASM	8

Message from our Chair



Welcome to the final Newsletter for 2015. 2015 has been a busy year for COGNO and I am happy to report, also a successful one.

COGNO's membership continues to grow, the new VERTU study opened to recruitment, our second 'Ideas Generation Workshop' was held in March with a number of ideas in development, a Strategic Planning meeting was held in June with a report to be circulated shortly to members for input, and a very successful ASM was held in

October. COGNO Executive continues to strengthen existing relationships with international trials groups as well as seeking new collaborations. A major event in 2016 is COGNO's ASM in September in Sydney, when COGNO will also be hosting the 13th Asian Society for Neuro-Oncology (ASNO) Meeting. The 2016 ASM co-convenors, Dr Liz Hovey and Dr Cecelia Gzell, along with the organising committee, have already confirmed 7 international speakers for what promises to be an outstanding educational and networking opportunity.

We have been fortunate in the past few months with a number of donations being received. Of particular note is the Race4Stace event organised by Cameron Harvey in memory of his late partner, Stacey Siegert. A very big and heartfelt thank you to Cameron.

Congratulations to Robyn Leonard on her hard work in establishing the Brain Cancer Biobanking Australia (BCBA) and for her ongoing efforts in seeking funding for the BCBA.

I wish you all a very happy holiday season and hope that you all get some time away from work.

Thanks again to everyone on the COGNO Executive and at Operations: a wonderful and enthusiastic team that has done so much to improve the care of our patients.

Mark Rosenthal
Group Chair

8th COGNO ANNUAL SCIENTIFIC MEETING
'WHERE THE FUTURE LIES'
Friday 23rd - Saturday 24th October 2015
Stamford Plaza Brisbane, Queensland, Australia

Congratulations to Dr Cecelia Gzell (Convenor) and the organising committee on a successful ASM! The scientific program, with international speakers Professor Martin van den Bent, Professor Vinay Puduvalli and Professor Amy Heimberger, as well as a number of Australian experts, was very well received, in particular the sessions with Professor van den Bent.

(continues on page 6)

GETTING TO KNOW COGNO'S MANAGEMENT COMMITTEE MEMBERS



A/Prof Matthew Foote is a member of the COGNO Management and Scientific Advisory Committees.

How did you become involved in COGNO?

I first became interested in Neuro-oncology as a trainee and was present at a meeting in Sydney

when COGNO was initially established. My career path and fellowship in Canada was in neuro-oncology so on my return to Australia in 2009 I was keen to get involved as I saw that there was a lot of opportunity to make a difference in this relatively small and subspecialised field. Soon after returning I made my interest in being involved in Neuro-oncology trials known and was fortunate enough to be elected on to the COGNO Management Committee. I am now also on the Scientific Advisory Committee. It has been rewarding to see the growth of COGNO over the last 5 years and I really enjoy being part of the development of new treatment approaches in the field.

Why did you become a radiation oncologist?

I first became interested in radiation oncology as an intern at the Gold Coast Hospital. I was speaking to a senior colleague who had just been accepted onto the training program and I was quizzing him as to why he chose radiation oncology. His response was something along the lines of - if you like a combination of medical imaging, patient contact and technology then it is the ideal specialty.

He also said he had spoken to a number of Radiation Oncologists all of whom said that if they had their time again they would choose the same specialty. Looking back on this he was absolutely correct. I have not met a radiation oncologist in practice who wishes they did another specialty. I genuinely love my job.

My job now is somewhat different from what I initially anticipated owing to my subspecialty interest in stereotactic brain and body radiotherapy. Now with Gamma Knife® I treat a range of conditions like trigeminal neuralgia, AVMs, and many benign tumours. My practice is very different from a typical radiation oncologist in that approximately one third of my patients don't have cancer.

What is a typical day for you?

My weekdays are usually extremely hectic. I wake up around 4:30 am and on the road either running or cycling at 4:45 am. I get home between 6-6:30am (usually still in the dark during winter) and get ready for work. I am usually at work just after 7am. My work day varies from

Monday to Friday but I often have clinical meetings at 7:30am and various multidisciplinary meetings. I have outpatient clinics in the mornings and reviews of patients on treatment. There is scheduled time to prepare patients for radiation therapy treatment (planning sessions) and times when I am directly on at the machines overseeing stereotactic treatments. If there is a spare hour this is often spent on research projects including a number of translational collaborations I have at the Translational Research Institute (TRI), Brisbane. This means a lot of meetings! Things usually wind up around 6pm, home by 6:30pm to put my two girls to bed at 7pm. Dinner, relax for an hour and then into bed before 10pm. There is usually not much spare time during the week which is why relaxing on the weekends is a priority.

What do you do in your 'spare' time?

I try not to have 'spare' time during the working week. I do a lot of exercise (running and cycling) but I see this as essential lifestyle choices and factor them into my weekly schedule (hence the early starts!). On weekends when I have spare time I spend as much time as I can with my family doing the usual things a father of two young girls does. This means going to the pet store, park time, pool time in summer and eating ice-cream most days.

How do you stay motivated to continue in your role?

My main role is a radiation oncologist specialising in brain, head and neck and skin cancers. In this role I see that there are a number of motivators that are all complementary. Firstly, dealing with patients and their loved ones is always a strong motivator. I think that this then motivates the research interest as this is where a real difference in outcomes can be made. Then I think that having community engagement is very important. I was on the board of the John Trivett Foundation until its merger with Cure Brain Cancer. I am still very involved with Cure Brain Cancer in Queensland. I find that dealing with the wider 'brain tumour community' continues to motivate me in research and clinical fields. So for me there are the three important aspects to my career that each are rewarding, complementary and a continual source of motivation.

What are you most proud of in your career?

Establishing and Co-directing the Gamma Knife® Centre of Queensland and the Princess Alexandra Hospital is my greatest achievement so far. This took a year of lobbying, raising capital and writing business plans. We have now started treatment and are the only public Gamma Knife® facility in Australia and over the coming years will establish a Centre of Excellence providing training for the Asia-pacific region. It also opens some unique research opportunities and collaborations internationally which is all very exciting.

STUDY & TRIAL UPDATES

CATNON (EORTC 26053-22054): *Phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma*

The CATNON study has now randomised 751 patients internationally (1407 patients were registered), reaching their target in mid-September 15. Our 13 Australian sites registered 191 patients of which 82 were recruited to the study which accounted to approx. 11% of the overall total contribution to the trial.

On behalf of the EORTC, the CTC would like to thank you for your dedication and commitment to the study thus far, your efforts are very much appreciated. The EORTC conducted an interim analysis in September to assess the data collected to date. All sites have now been informed of the recent EORTC IDMC recommendations (Letters dated the 26th October and 12th November 2015). Please contact the CATNON Trial Coordinator if you have any questions or your site has not received this information.

As always, the CATNON Trial Coordinator, is happy to provide any information that you may require. Please email catnon@ctc.usyd.edu.au if you have any questions or queries.

VERTU (COGNO 14/01): *VELiparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma. A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in patients with newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT).*

The VERTU study is now open to recruitment, following the activation of the first site on 28th October 2015. Congratulations to Prof Mark Rosenthal and his team at the Royal Melbourne Hospital for being the first site to complete all of the set-up activities required to start enrolment for VERTU. We would also like to thank all participating sites for their patience and understanding while the contractual aspects of the trial were getting finalised and the arrival of study drug to our central pharmacy was being organised.

At this moment, 5 sites have opened to recruit patients and another 3 are expected to be opened before end of 2015. We aim to open all 12 participating study sites by February 2016.

On 30th November 2015, the first patient was randomised in the VERTU trial. Congratulations to Dr Helen Wheeler and her team at the Royal North Shore Hospital for enrolling the first patient into the VERTU study. We hope to achieve the target accrual of 120 patients in the next 24 months.

The VERTU Trial Coordinator is more than happy to provide any information that you may require on this study. Please email vertu@ctc.usyd.edu.au if you have any queries.

VERTU - PARTICIPATING SITE STATUS						
No	Site name	State	Principal Investigator	Site status	Site initiation*	Site activation*
1	Royal North Shore Hospital	NSW	Helen Wheeler	Active	<u>26-Oct-15</u>	<u>09-Nov-15</u>
2	Chris O'Brien Lifehouse	NSW	John Simes	Active	<u>25-Nov-15</u>	<u>26-Nov-15</u>
3	Liverpool Hospital	NSW	Eng-Siew Koh	Initiated	<u>04-Dec-15</u>	Dec-15
4	Royal Melbourne Hospital	VIC	Mark Rosenthal	Active	<u>21-Oct-15</u>	<u>28-Oct-15</u>
5	University Hospital Geelong	VIC	David Ashley	Submission in progress	Dec-15	Jan-16
6	Epworth Healthcare	VIC	Ross Jennens	Initiated	<u>02-Dec-15</u>	Dec-15
7	Monash Medical Centre	VIC	Ronnie Freilich	Submission in progress	Dec-15	Dec-15
8	Royal Brisbane and Women's Hospital	QLD	Zarnie Lwin	Active	<u>02-Nov-15</u>	<u>09-Nov-15</u>
9	Princess Alexandra Hospital	QLD	Matthew Foote	Submission in progress	Jan-16	Jan-16
10	Royal Adelaide Hospital	SA	Nimit Singhal	Submission in progress	Jan-16	Jan-16
11	Sir Charles Gairdner Hospital	WA	Anna Nowak	Submission pending	Feb-16	Feb-16
12	Royal Hobart Hospital	TAS	Rosemary Harrup	Active	<u>23-Nov-15</u>	<u>02-Dec-15</u>
* <u>underlined</u> = actuals				Current at 02 Dec 2015		

NEW CONCEPTS/TRIALS IN DEVELOPMENT

ACED (COGNO14/02): Phase II randomised placebo-controlled, double blind, multisite study of acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive HGG requiring treatment with dexamethasone - the ACED trial.

The ACED study aims to recruit initially 18 participants across 3 sites. If funding is successful, it is anticipated to increase to 84 patients across 12 sites. Central ethics approval was granted at the end of August 15 and the first site (Liverpool Hospital) is well underway in completing all governance and regulatory approvals to allow activation. It is anticipated this study will commence recruitment in the first quarter of 2016. Meanwhile, the study team is working diligently to prepare all study documents, systems and procedures to facilitate an efficient conduct of the trial. Please email aced@ctc.usyd.edu.au if you have any queries.

DO YOU HAVE A NEW CONCEPT? COGNO is always looking to develop new studies - from inception through to full protocol development and managing feasibility and operational issues. We aim to help progress and support development of important clinical trial questions. If you would like to propose a concept or have an amazing idea for a COGNO clinical trial, please contact us on cogno@ctc.usyd.edu.au or call and chat to Renee Swanson, Associate Oncology Program Manager - Development, on 02 9562 5374. The SAC meets regularly and Renee and the team can assist you to develop and progress your idea or assist you with completion of the Trial Concept Outline form available at www.cogno.org.au.



GBM AGILE (an Adaptive Global Innovative Learning Environment): Data from COGNO's CABARET study contributed to the mathematical modelling and design of this new adaptive clinical trial platform. The official media launch was held on Friday 13 November in Washington and Sydney. Dr Mustafa Khasraw is the Australian liaison on the GBM AGILE executive committee. Further details re GBM AGILE are available on <http://www.cogno.org.au/docview.aspx?id=283> and <http://sydney.edu.au/news-opinion/news/2015/11/13/brain-cancer-experts-crowdsource-a-cure-for-deadly-glioblastoma.html>.

Mustafa Khasraw and Joe Biden at GBM AGILE Launch in Washington

MEMBERSHIP UPDATE

COGNO now has 460 members! Help us expand our Group's expertise and networking capacity. If you know someone who would like to join, you can refer prospective members to our online membership application on our website (www.cogno.org.au) or office (cogno@ctc.usyd.edu.au).

BRAIN CANCER BIOBANKING AUSTRALIA (BCBA)

As reported in an earlier newsletter (issue 18, interview with Robyn Leonard), the BCBA (previously NBCBC) consortium was established under the umbrella of COGNO with the goal of accelerating brain cancer research and the translation of that research into improved outcomes in patient care. Phase 1 of the BCBA website is now live with work on phase 2 (building the online register of biospecimens) commencing in early 2016. Please visit www.bcba.org.au to find out more about the BCBA.

UPDATE FROM THE QUALITY OF LIFE OFFICE

The Quality of Life (QOL) Office is funded by Cancer Australia to provide advice and support to members of COGNO on assessing patient-reported outcomes (PROs) in cancer clinical trials. For any queries regarding the QOL Office please email margaret-ann.tait@sydney.edu.au.

The QOL Office has been working on a number of projects this year including a systematic review of modes of PRO questionnaire administration to determine whether mode of administration (pen and paper, electronic, phone interview) leads to bias or differences in response rates. Refer <http://www.pocog.org.au/qolfaq.aspx?category=2> for frequently asked questions and <http://www.pocog.org.au/news.aspx?id=152> to see the published systematic review.

QOL is available to assist COGNO members with PRO research queries via https://sydneypsy.qualtrics.com/SE/?SID=SV_eV85Bh9eW84R0ln.

PROTOCOL CHECKLIST WORKSHOP, 2-3 JUNE 2015, SYDNEY

Marina Kastelan, COGNO Scientific Advisory Committee member, attended the Quality of Life PROtocol Checklist Workshop - Marina's report appears below.

With the support of COGNO, I was fortunate to attend a two day PROtocol Checklist Workshop held by the Quality of life office in June this year. The two day, very comprehensive workshop, was compiled of sessions including Patient-Reported Outcomes (PRO's) terminology and conceptual model which was delivered by Prof Madeleine King of PoCoG, the Psycho-Oncology Co-Operative research Group. Madeleine spoke of the background, rationale, objectives & hypotheses of "the protocol" with introduction to the PROtocol checklist. The PROtocol checklist was provided & the link to downloadable version was also given - download via the PoCoG website. Other useful information was also provided such as the PRO CoMiDA form (Patient Reported Outcome Completion & Missing Data Form) & FACT-G.

Day one also had sessions on PRO questionnaires, what's available & which are the best to use. The day ended with "economic evaluation and cost utility analysis". Throughout the sessions, real life trial examples were used, we were shown where issues occurred or where things may have been done better - this provided great insight with real life examples.

Day two began with a session on PRO questionnaire administration discussing amongst other things, "inclusion and exclusion criteria specific to PRO assessment; timing of PRO assessments and quality assurance". The day then went on to discuss the effects and impact of missing data on power and on bias.

Discussion about endpoints and statistical considerations, including power and sample size, assessment of missing data and handling missing data ended the day. Ultimately, the greatest thing I learnt was the support offered and available for the QOL office <http://www.pocog.org.au/content.aspx?page=qolresources>.

The two day workshop was more enjoyable than I'd anticipated, was valuable and gave great insight to Patient-Reported Outcomes. I thank COGNO for supporting me to attend this workshop.

RACE4STACE, 7 NOVEMBER 2015, SYDNEY



This was an inaugural fundraising event organised by Cameron Harvey in memory of his partner, Stacey Siegert, who lost her battle with brain cancer last year. Race4Stace was very successful due entirely to the hard work and efforts of Cameron (and all his family and friends). The event attracted television coverage, including an interview with Cameron and Dr Liz Hovey, one of Stacey's oncologists and COGNO SAC chair (interview available on <https://au.tv.yahoo.com/sunrise/video/watch/30028350/tv-crews-hit-the-water-for-cancer-research/#page1>). To date, Race4Stace has raised over \$16,000 for COGNO. Our sincere thanks and appreciation go to Cameron.



Cameron Harvey and Liz Hovey with Weekend Sunrise presenters
L to R: Talitha Cummins, Cameron, Edwina Bartholomew, Liz and Andrew O'Keefe



In addition to the Race4Stace, COGNO has recently been the recipient of donations in memory of loved ones who have passed away from brain cancer. If you know anyone who is interested in donating to COGNO, a donations form is available on the COGNO website (www.cogno.org.au).

Top: Approaching the finish line, Middle and bottom: Channel 7 and Channel 9 camera crews in battle

8th COGNO ASM 'WHERE THE FUTURE LIES'
 Friday 23rd - Saturday 24th October 2015, Stamford Plaza Brisbane, Queensland, Australia

(continued from page 1)

A copy of the ASM conference booklet (including abstracts) is available on <http://www.cogno.org.au/content.aspx?page=cognoasm2015>.


We thank our sponsors for their support of the 2015 ASM. The COGNO Scientific Program has been developed independent of sponsor involvement.




Congratulations to our award and grant recipients as listed below:



Most Outstanding Oral Presentation:
 A/Prof Michael Back's presentation on *Patients with Favourable Anaplastic Glioma who relapse after definitive intensity modulated radiation therapy have a pattern of relapse involving distant brain sites and ventricular*



Most Outstanding Poster Presentation:
 Miss Joanna Macdonald's poster presentation on *Crossing the great divide: aptamer engineering for targeted brain metastasis treatment*



COGNO/Bristol-Myers Squibb Young Investigator Award:
 Dr Katrina Morris' poster presentation on *Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a UK nationally coordinated approach to delivery and prospective evaluation*



Cecelia Gzell with COGNO Neuro-Oncology Nurse/Care Coordinator Travel Grant recipient Ms Emma Daly
 (grant funded by Bridge 2 Bridge cyclists)



COGNO/Cancer Institute NSW Travel Grant recipient Ms Manuri Gunawardena

(continues on page 7)

8th COGNO ASM 'WHERE THE FUTURE LIES'

Friday 23rd - Saturday 24th October 2015
 Stamford Plaza Brisbane, Queensland, Australia

(continued from page 6)

MANAGEMENT COMMITTEE

Prof Mark Rosenthal (Chair)
 Prof John Simes (Deputy Chair)
 Dr Liz Hovey (Treasurer)
 Dr Eng-Siew Koh (Secretary)
 A/Prof Meera Agar
 A/Prof Kate Drummond
 Ms Marcia Fleet
 Dr Matthew Foote
 Prof Terry Johns
 Ms Robyn Leonard

SCIENTIFIC ADVISORY COMMITTEE

Dr Liz Hovey (Chair)
 Dr Eng-Siew Koh (Deputy Chair)
 A/Prof Meera Agar
 Ms Liz Barnes
 A/Prof Kate Drummond
 Dr Matthew Foote
 Dr Lindy Jeffree
 Prof Terry Johns
 Ms Marina Kastelan
 Dr Danette Langbecker
 Ms Robyn Leonard
 Dr Kerrie McDonald
 Dr Anna Nowak
 Prof Mark Rosenthal
 Dr Gail Ryan
 Prof John Simes
 Ms Renee Swanson
 Dr Helen Wheeler

OPERATIONS EXECUTIVE COMMITTEE

Prof Mark Rosenthal (Chair)
 Prof John Simes (Deputy Chair)
 Ms Liz Barnes
 Ms Jenny Chow
 Mrs Merryn Hall
 Dr Liz Hovey
 Dr Mustafa Khasraw
 Dr Eng-Siew Koh
 Mrs Ann Livingstone
 Ms Renee Swanson

Below is a thank you letter we received from Dr Haresh Kunhiparambath, Sponsored Foreign Delegate.

Dear sir/madam,

I reached India yesterday night. Let me thank you all from the bottom of my heart for all the help given to me when I was there. I don't have words to tell about the hospitality and care that you have given. I cherished every moment I spent there. I really enjoyed the academic content that was well balanced addressing the advances and research in neuro-oncology. The lessons that I learned will for sure help to modify the neuro-oncology practices at my institute. I am sure that all those discussions will be of interest to my colleagues here also. This COGNO ASM will remain to be one of the best academic events that I have attended.

Once again thank you very much.
 Haresh Kunhiparambath



Haresh with Cecelia Gzell

Congratulations to the MSD Hubert Stuerzel Memorial Education Award recipient Andrew Gogos. The award was presented this year at the COGNO ASM Dinner. Andrew was unable to attend to receive his award which was accepted on his behalf by Mark Rosenthal.

The purpose of this award is to encourage education in the field of neuro-oncology. The award will provide up to \$15,000 for the successful recipient to attend a major international neuro-oncology meeting (eg. SNO, EANO, Perspectives in Neuro-oncology) and undertake a preceptorship in neuro-oncology during 2015-2016.



COGNO Chair Mark Rosenthal with MSD representative Gabrielle Carroll



Congratulations to our Chair, Mark Rosenthal, who takes on the mantle of President of ASNO. The ASNO presidential medallion was formally presented to Mark by Dr Zarnie Lwin on behalf of ASNO during the 2015 ASM Dinner.

(continues on page 8)

8th COGNO ASM 'WHERE THE FUTURE LIES'

Friday 23rd - Saturday 24th October 2015

Stamford Plaza Brisbane, Queensland, Australia

(continued from page 7)



Professor Martin van den Bent



Professor Vinay Puduvalli with Cecelia Gzell



Professor Amy Heimberger



Save the Date! 13TH Asian Society for Neuro-Oncology (ASNO) Meeting / 9TH COGNO Annual Scientific Meeting "Neuro-Oncology: is the landscape changing?" Sunday 11th - Wednesday 14th September 2016, Sydney, Australia

Confirmed international speakers include:

- **Professor Roger Stupp MD**, Professor and Chairman, Department of Oncology & Director, University Hospital Cancer Center, University of Zurich, Zurich/Switzerland
- **Professor Mitchel Berger MD FACS FAANS**, Professor and Chairman, Department of Neurological Surgery, UCSF, USA
- **Professor Paul Mischel MD**, Head, Laboratory of Molecular Pathology, Ludwig Institute for Cancer Research, USA and Professor, University of California San Diego, USA
- **Associate Professor Arjun Sahgal BSc MD FRCPC**, Associate Professor of Radiation Oncology and Surgery, University of Toronto, Canada and Deputy Chief, Department of Radiation Oncology, Odette Cancer Centre, Canada
- **Professor W. K. Alfred Yung MD**, Professor and Chair of Neuro-oncology, The University of Texas MD Anderson Cancer Center, USA
- **Professor Gregory Riggins MD PhD**, Professor of Neurosurgery and Oncology, Johns Hopkins University School of Medicine, USA
- **Assistant Adjunct Professor Mary Lovely PhD RN CNRN**, Assistant Adjunct Professor, UCSF School of Nursing, USA

For further information please visit our website <http://www.cogno.org.au/content.aspx?page=cognoasm-home2016>, or contact cogno@cogno.org.au if you wish to be added to our mailing list. We look forward to welcoming you to Sydney next year.



COGNO CONTACTS

Renee Swanson

Associate Oncology Program Manager - Development
(Mon, Wed, Thu)
E: renee.swanson@ctc.usyd.edu.au
T: (02) 9562 5374

Merryn Hall

Associate Oncology Program Manager - Operational
(Mon, Tue, Wed)
E: merryn.hall@ctc.usyd.edu.au
T: (02) 9562 5023

Martijn Oostendorp

ACED and VERTU Trial Coordinator
(Mon-Fri)
E: aced@ctc.usyd.edu.au
E: vertu@ctc.usyd.edu.au
T: (02) 9562 5372

Elise Robertson

CATNON and CABARET Trial Coordinator
(Mon-Fri)
E: catnon@ctc.usyd.edu.au
E: cabaret@ctc.usyd.edu.au
T: (02) 9562 5094

Mustafa Khasraw

CTC Clinical Lead for COGNO
E: mustafa.khasraw@ctc.usyd.edu.au

Felicia Roncolato

COGNO Research Fellow
E: felicia.roncolato@ctc.usyd.edu.au

Jenny Chow

Executive Officer
(Mon, Tues, Wed, Fri)
E: cognoeo@ctc.usyd.edu.au
T: (02) 9562 5389

Yi Feng

Admin Assistant
(Wed afternoon, Thur, Fri morning)
E: yi.feng@ctc.usyd.edu.au
T: (02) 8036 5238

Mythily Mariasegaram

BCBA Project Coordinator
(Mon, Tue)
E: mythily.mariasegaram@ctc.usyd.edu.au
T: (02) 8036 5244

COGNO Coordinating Centre

NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450
T: +61 2 9562 5000
F: +61 2 9562 5094
E: cogno@ctc.usyd.edu.au